Colo-rectal Cancer Clinical Trial
Official title:
Specimen Collection Study for Cancer
Verified date | February 2022 |
Source | Freenome Holdings Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.
Status | Completed |
Enrollment | 3275 |
Est. completion date | November 25, 2019 |
Est. primary completion date | November 25, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | COHORT A Inclusion Criteria: - 50-84 years of age (inclusive) at the time of screening - Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s) - At least 7 days before but no more than 6 months after the most recent colonoscopy - Able and willing to provide blood and stool (optional) samples per protocol - Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study Key Exclusion Criteria: - Personal history of colorectal cancer, colorectal adenomas (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer (other than most recent diagnosis) - Colonoscopy within the previous 9 years (other than most recent diagnosis) - Overt rectal bleeding within the previous 30 days - Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study. - Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy. - If female, known to be pregnant. COHORT B Inclusion Criteria: - 50-84 years of age (inclusive) at the time of screening - Planning to undergo a screening colonoscopy within 75 days after providing signed informed consent - Able and willing to provide blood and stool (optional) samples per protocol - Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study Key Exclusion Criteria: - Personal history of colorectal cancer, colorectal adenoma (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer - Colonoscopy within the previous 9 years - Overt rectal bleeding within the previous 30 days - Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study. - Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy. - If female, known to be pregnant. COHORT C Inclusion Criteria: - At least 18 years of age (inclusive) at the time of screening - Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s) - At least 7 days before but no more than 6 months after the most recent colonoscopy - Able and willing to provide blood and stool (optional) samples per protocol - Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study Exclusion Criteria: - Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study. - Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy. - If female, be known to be pregnant. |
Country | Name | City | State |
---|---|---|---|
Canada | Forzani and MacPhail Colon Cancer Screening Centre | Calgary | Alberta |
United States | Asheville Gastroenterology Associates | Asheville | North Carolina |
United States | Delta Research Partners | Bastrop | Louisiana |
United States | Washington Gastroenterology | Bellevue | Washington |
United States | Gastroenterology Associates of Fairfield County | Bridgeport | Connecticut |
United States | Commonwealth Clinical Studies | Brockton | Massachusetts |
United States | Del Sol Research Management | Chandler | Arizona |
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | Gastroenterology Associates of Tidewater | Chesapeake | Virginia |
United States | Precision Research Institute | Chula Vista | California |
United States | Verity Research Inc | Fairfax | Virginia |
United States | Cumberland Research Associates | Fayetteville | North Carolina |
United States | Palmetto Research | Hialeah | Florida |
United States | Clinical Research of Homestead | Homestead | Florida |
United States | Clinical Research Associates | Huntsville | Alabama |
United States | The Jackson Clinic | Jackson | Tennessee |
United States | Preferred Research Partners | Little Rock | Arkansas |
United States | New Orleans Research Institute | Metairie | Louisiana |
United States | Digestive and Liver Disease Specialists | Norfolk | Virginia |
United States | Advanced Research Institute | Ogden | Utah |
United States | Quality Clinical Research | Omaha | Nebraska |
United States | Diverse Research Solutions | Oxnard | California |
United States | Advanced Gastroenterology Associates, LLC | Palm Harbor | Florida |
United States | Wake Research Associates | Raleigh | North Carolina |
United States | Rockford Gastroenterology | Rockford | Illinois |
United States | Precision Research Institute | San Diego | California |
United States | Louisiana Research Center | Shreveport | Louisiana |
United States | Del Sol Research Management | Tucson | Arizona |
United States | Del Sol Research Management, | Tucson | Arizona |
United States | Trial Management Associates | Wilmington | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Freenome Holdings Inc. |
United States, Canada,
Putcha G, Liu T-Y, Ariazi E, Bertin M, Drake A, Dzamba M, Hogan G, Kothen-Hill S, Liao J, Li K, Mahajan S, Palaniappan K, Sansanwal P, St John J, Ulz P, Wan N, Warsinske H, Weinberg D, Yang R, Lin J. Blood-based detection of early-stage colorectal cancer
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnosis of colorectal cancer or advanced adenomas in patients undergoing routine screening colonoscopy, or post-colonoscopy | Clinically annotated plasma samples from participants will undergo multi-omic analyses to characterize cell-free biomarkers. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05074966 -
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
|
Phase 3 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT05056389 -
Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)
|
Phase 1 | |
Completed |
NCT04551014 -
Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm
|
N/A | |
Completed |
NCT04551001 -
Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy
|
N/A | |
Recruiting |
NCT04270500 -
The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period
|
N/A | |
Recruiting |
NCT03667911 -
Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy
|
N/A | |
Not yet recruiting |
NCT04073680 -
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05572684 -
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03567850 -
Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
|
N/A | |
Recruiting |
NCT05870332 -
Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
|
||
Completed |
NCT04534218 -
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT05590117 -
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
|
Early Phase 1 | |
Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04195646 -
Computer Aided Detection of Polyps During Colonoscopy Procedures
|
N/A | |
Not yet recruiting |
NCT03618329 -
Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM.
|
N/A | |
Not yet recruiting |
NCT03261752 -
New Genes in the Carcinogenesis of Colorectal Cancer
|
||
Terminated |
NCT03621982 -
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
|
Phase 1 |